Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pharmacokinetics of the Chimeric Anti-GD2 Antibody, ch14.18, in Children With High-Risk Neuroblastoma

NCT01418495 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01418495
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01418495 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pharmacokinetics of the Chimeric Anti-GD2 Antibody, ch14.18, in Children With High-Risk Neuroblastoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Observational
Overall status
Completed
Start date
May 26, 2011
Completion date
Not reported
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

localized resectable neuroblastoma, localized unresectable neuroblastoma, neurotoxicity syndrome, pain, regional neuroblastoma, stage 4 neuroblastoma, stage 4s neuroblastoma